But the diagnostic test, which checks to see if a patient's tumor carries a mutation in a gene coding for anaplastic lymphoma kinase,
called ALK, is just $ 250.
About 4 percent of NSCLCs are driven by genetic aberrations
called ALK gene rearrangements, according to Farace.
Not exact matches
Originally designed to block a kinase
called MET, it was later discovered to target
ALK as well.